Cencora, Inc.

NYSE:COR Stock Report

Market Cap: US$51.8b

Cencora Future Growth

Future criteria checks 2/6

Cencora is forecast to grow earnings and revenue by 5.9% and 5.6% per annum respectively. EPS is expected to grow by 9.2% per annum. Return on equity is forecast to be 53.8% in 3 years.

Key information

5.9%

Earnings growth rate

9.20%

EPS growth rate

Healthcare earnings growth18.3%
Revenue growth rate5.6%
Future return on equity53.80%
Analyst coverage

Good

Last updated11 May 2026

Recent future growth updates

Analysis Article • Aug 09

Cencora, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

NYSE:COR 1 Year Share Price vs Fair Value Explore Cencora's Fair Values from the Community and select yours Cencora...

Recent updates

New Narrative • May 09

Specialty And AI Investments Will Shape A Stable Yet Constrained Future Trajectory

Catalysts About Cencora Cencora is a pharmaceutical services company that supports manufacturers, health systems, physician practices and pharmacies across the global pharmaceutical supply chain. What are the underlying business or industry changes driving this perspective?
Narrative Update • May 08

COR: Share Repurchases And CFO Transition Will Support Long Term Upside

Analysts now estimate Cencora’s fair value at about $373, down from roughly $403. This reflects slightly higher assumed discount rates and a lower future P/E multiple, partly offset by a marginally stronger profit margin profile in their updated models.
Seeking Alpha • May 07

Cencora Earnings Review: The Selloff Was Overdone In My View

Summary Cencora reported Q2 results with 3.8% revenue growth and a 129% EPS increase, but shares fell sharply, apparently due to a revenue miss. Despite a forward P/E of ~14 and manageable debt, COR faces thin margins, client concentration risks, and headwinds from biosimilars and drug price reductions. Management remains confident, targeting $3B in free cash flow and $1B in share repurchases for 2026, with ongoing M&A to expand specialty services. I view the recent sell-off as an overreaction, presenting a 'buy the dip' opportunity given COR's robust fundamentals and undervaluation. Read the full article on Seeking Alpha
Narrative Update • Apr 24

COR: CFO Transition And Disciplined Buybacks Will Support Long-Term Upside

Analysts have trimmed their price target on Cencora by about $5 to reflect slightly updated assumptions around fair value, revenue growth, profit margins, and future P/E, while still viewing the shares through a similar overall framework. What's in the News Cencora plans a leadership change, with long serving Chief Financial Officer James F.
Narrative Update • Apr 08

COR: Rare Disease Collaborations And Distribution Reach Will Support Long-Term Upside

Analysts have kept their price target for Cencora steady at $407.92, citing only very small tweaks to inputs like revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the business. What's in the News Cencora announced that Chief Financial Officer James F.
Narrative Update • Mar 25

COR: Rare Disease Partnerships Will Support Long-Term Upside For Capital Markets Access

Analysts have adjusted their fair value estimate for Cencora to about $408 from $410, reflecting small tweaks to assumptions around the discount rate, revenue growth, profit margin, and future P/E rather than a major shift in the story. What's in the News Cencora plans for Chief Financial Officer James F.
Narrative Update • Mar 10

COR: Capital Markets And Rare-Disease Services Will Support Long-Term Upside

Analysts now place Cencora's fair value at $410.00, up from $403.79. This change reflects small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates in their models.
Narrative Update • Feb 24

COR: 3PL Expansion And M&A Options Will Shape Balanced Long-Term Upside

Analysts have nudged their price target for Cencora higher to about $404 from roughly $400, citing refreshed assumptions around revenue growth, profitability and a modestly higher future P/E multiple. What's in the News Cencora is expanding its third party logistics capabilities in the United States and Europe, including adding NextPharma Logistics across Germany, Austria and Switzerland and planning a new 3PL facility in Italy in 2026, alongside increased cold chain capacity across its European network (company announcement).
Analysis Article • Feb 12

Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Cencora, Inc.'s ( NYSE:COR ) recent earnings report didn't offer any surprises, with the shares unchanged over the last...
Narrative Update • Feb 08

COR: Buybacks And 3PL Expansion Will Support Long-Term Upside Potential

Analysts have nudged their projected fair value for Cencora to $399.80 from $396.80, citing updated assumptions around revenue growth, profit margins, the discount rate and a slightly lower future P/E multiple. What's in the News Cencora completed a share repurchase program totaling 4,895,419 shares, or 2.49% of shares, for US$1,118.1m under the buyback announced on May 1, 2024 (Buyback Tranche Update).
Narrative Update • Jan 23

COR: Global 3PL Expansion And Logistics Investments Will Support Long-Term Upside

Analysts have nudged their price target on Cencora higher to about US$397 from roughly US$388. This reflects refreshed assumptions on revenue growth, profit margins and future P/E levels in their models.
Narrative Update • Jan 09

COR: Global 3PL Buildout And Higher Dividend Will Support Long-Term Upside

Analysts have nudged their price target on Cencora higher to about $388, citing slightly lower modeled revenue growth, a modestly stronger profit margin, and a small uptick in assumed future P/E as key drivers of the updated view. What's in the News Cencora announced investments to expand its third party logistics capabilities in the United States and Europe, including broader specialty logistics services for pharmaceutical companies worldwide.
Narrative Update • Dec 16

COR: Global 3PL Expansion And Dividend Increases Will Offset Goodwill Impairment Risks

Analysts have slightly raised their price target on Cencora, increasing fair value by about 1.8 dollars per share as they factor in marginally stronger projected revenue growth, a modestly higher long term profit margin, and a steady future earnings multiple. What's in the News Cencora is making major investments to expand its third party logistics network, including a new 500,000 square foot 3PL facility in Texas by 2028 and a tripling of ultra low and cryogenic storage capacity in the United States, to support growing demand for specialty medicines such as cell and gene therapies (company announcement).
Narrative Update • Dec 02

COR: Automated Distribution Expansion And Margins Will Balance Storage And Dividend Risks

Analysts have modestly raised their price target for Cencora, increasing the estimated fair value by $2.71 to $384.79. This adjustment is based on slight improvements in profit margin expectations and valuation multiples.
Narrative Update • Nov 18

COR: Automated Expansion And Margin Gains Will Offset Ongoing Legal Risks

Analysts have raised their price target for Cencora, increasing the estimated fair value from $338.29 to $382.07. They cite strengthened profit margin expectations, even though there is a slightly higher discount rate and moderated revenue growth forecasts.
Narrative Update • Nov 04

COR: Ongoing Litigation Settlement And Buybacks Will Shape Healthcare Delivery Evolution

Analysts have raised their price target for Cencora by $5 to $338.29. They cite updated forecasts for slightly lower near-term revenue growth, but a stronger overall fair value assessment.
Narrative Update • Sep 04

Digital Infrastructure And Specialty Services Will Redefine Healthcare Delivery

With both Cencora’s net profit margin and consensus revenue growth forecasts holding steady, analysts have maintained their price target unchanged at $333.29. What's in the News Cencora completed the repurchase of 4,895,419 shares (2.49% of shares outstanding) for $1,118.1 million under its buyback program announced in May 2024; no shares were repurchased from April to June 2025.
Analysis Article • Aug 09

Cencora, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

NYSE:COR 1 Year Share Price vs Fair Value Explore Cencora's Fair Values from the Community and select yours Cencora...
Seeking Alpha • Feb 25

Cencora: Great Track Record And Outlook, But Valuation Does Not Offer Upside

Summary Cencora has a solid industry position in an oligopolistic market with supernormal return ratios and solid stock price returns. 1QFY25 results, as well as the near-term outlook, are also solid, with EPS guided by management to grow in the low double digits in FY25. Moreover, the company also has a decent long-term outlook, with management as well as analysts guiding EPS to grow at an 8-12% growth rate. Despite a solid growth outlook, Cencora's valuation looks to have factored in much of these tailwinds, which has led me to issue a hold rating on the stock. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NYSE:COR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2028382,0503,2444,1845,1749
9/30/2027358,9892,9823,4554,69612
9/30/2026337,7733,4743,1174,43912
3/31/2026328,6802,5491,5582,276N/A
12/31/2025325,7781,6253,6074,289N/A
9/30/2025321,3331,5543,2073,875N/A
6/30/2025316,6541,8971,1421,742N/A
3/31/2025310,2321,6933,5754,110N/A
12/31/2024303,1931,396-638-119N/A
9/30/2024293,9591,5092,9983,485N/A
6/30/2024283,8311,8563,8314,311N/A
3/31/2024276,5371,8522,1122,578N/A
12/31/2023271,5791,8673,6304,086N/A
9/30/2023262,1731,7453,4533,911N/A
6/30/2023254,4251,6892,7933,249N/A
3/31/2023247,5431,6172,4472,913N/A
12/31/2022241,8051,7292,0572,550N/A
9/30/2022238,5871,6992,2072,703N/A
6/30/2022236,3251,8422,0612,548N/A
3/31/2022229,6661,7272,8513,347N/A
12/31/2021221,1011,6142,1742,627N/A
9/30/2021213,9891,5402,2282,667N/A
6/30/2021204,321-3,7442,5642,956N/A
3/31/2021196,282-3,7471,2841,660N/A
12/31/2020194,546-3,2222,6002,967N/A
9/30/2020189,894-3,4091,8372,207N/A
6/30/2020186,2871,5701,2501,581N/A
3/31/2020186,1591,5821,9432,236N/A
12/31/2019182,061649N/A2,008N/A
9/30/2019179,589855N/A2,344N/A
6/30/2019177,248956N/A2,337N/A
3/31/2019175,151930N/A2,592N/A
12/31/2018172,8661,190N/A1,880N/A
9/30/2018167,9401,658N/A1,411N/A
6/30/2018163,7631,081N/A2,126N/A
3/31/2018159,327855N/A1,059N/A
12/31/2017155,441979N/A1,945N/A
9/30/2017153,144364N/A1,504N/A
6/30/2017151,584855N/A1,478N/A
3/31/2017149,7591,154N/A1,915N/A
12/31/2016148,3101,346N/A1,997N/A
9/30/2016146,8501,428N/A3,178N/A
6/30/2016144,7591,643N/A2,986N/A
3/31/2016142,1111,508N/A3,916N/A
12/31/2015139,082391N/A3,777N/A
9/30/2015135,962-138N/A3,922N/A
6/30/2015132,080-431N/A3,591N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: COR's forecast earnings growth (5.9% per year) is above the savings rate (3.5%).

Earnings vs Market: COR's earnings (5.9% per year) are forecast to grow slower than the US market (16.8% per year).

High Growth Earnings: COR's earnings are forecast to grow, but not significantly.

Revenue vs Market: COR's revenue (5.6% per year) is forecast to grow slower than the US market (11.6% per year).

High Growth Revenue: COR's revenue (5.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: COR's Return on Equity is forecast to be very high in 3 years time (53.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 06:59
End of Day Share Price 2026/05/20 00:00
Earnings2026/03/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cencora, Inc. is covered by 32 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Eric ColdwellBaird
Glen SantangeloBarclays